Azenta sells ultra-low-temperature freezers, automated sample storage systems and a sample management services business that holds and tracks biological specimens for pharma and life-science customers. Its edge is the recurring nature of that sample-handling work, which ties customers to its storage and logistics platforms once a biobank is built out. Revenue grew 12.0% over the trailing period, but operating margin is still slightly negative at -2.3% and return on equity is -7.0%, so the investment case rests on operating leverage arriving as growth continues. The stock trades at 29.1x forward earnings, a premium that assumes that margin recovery is close, which is the central question to test. With a 44.0% gross margin and no index membership, the name sits outside most passive flows, so any re-rating would need to come from fundamentals. It merits a deeper look if the next few quarters show operating margin moving clearly toward positive territory.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 20 Oct 2026, 14:06 CEST | Fair value | $11.51 | $11.68 | $34.84 |
| 20 Oct 2026, 14:06 CEST | Rating | Overvalued | first publication | $34.84 |
| 15 Oct 2026, 00:00 CEST | Fair value | $11.68 | $12.58 | $37.87 |
| 12 Oct 2026, 00:00 CEST | ACCE price target | $36.00 | first publication | $37.72 |
| 8 Oct 2026, 00:00 CEST | Fair value | $12.58 | $14.01 | $39.35 |
| 7 Oct 2026, 00:00 CEST | Fair value | $14.01 | $13.25 | $42.73 |
| 4 Oct 2026, 00:00 CEST | Fair value | $13.25 | $10.82 | $38.75 |
| 27 Sept 2026, 00:00 CEST | Fair value | $10.82 | $10.98 | $34.02 |
| 21 Sept 2026, 00:00 CEST | Fair value | $10.98 | $11.20 | $33.24 |
| 19 Sept 2026, 00:00 CEST | Fair value | $11.20 | $11.58 | $33.63 |
Answered from Azenta Inc. fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| AZTA Azenta Inc. | $36.50 | $12 | 217% above | - | -7.0% | 43 | 55 |
| BONEX.ST Bonesupport Holding AB (publ) | kr 319.80 | - | - | 81.5x | 24.5% | 88 | 72 |
| ALIF-B.ST AddLife AB (publ) | kr 180.70 | kr 133 | 36% above | 35.0x | 11.5% | 54 | 54 |
| SYNSAM.ST Synsam AB (publ) | kr 55.40 | kr 69 | 19% below | 13.9x | 23.4% | 67 | 63 |
| DYVOX.ST Dynavox Group AB (publ) | kr 68.65 | kr 45 | 54% above | 27.6x | 40.4% | 76 | 51 |
| ICUI ICU Medical Inc. Common Stock | $168.33 | $111 | 52% above | 134.7x | 1.4% | 43 | 50 |
| ANN.AX Ansell Limited | A$45.76 | A$40 | 15% above | 21.6x | 10.5% | 67 | 75 |
Where AZTA ranks against its sector peers on each metric.